



|                  |  |
|------------------|--|
| Title            | Development of a serodiagnostic multi-species ELISA against tick-borne encephalitis virus using subviral particles   |
| Author(s)        | Inagaki, Eri; Sakai, Mizuki; Hirano, Minato; Muto, Memi; Kobayashi, Shintaro; Kariwa, Hiroaki; Yoshii, Kentaro   |
| Citation         | Ticks and Tick-Borne Diseases, 7(5), 723-729<br><a href="https://doi.org/10.1016/j.ttbdis.2016.03.002">https://doi.org/10.1016/j.ttbdis.2016.03.002</a>  |
| Issue Date       | 2016-07  |
| Doc URL          | <a href="http://hdl.handle.net/2115/66556">http://hdl.handle.net/2115/66556</a>  |
| Rights           | © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license<br><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> |
| Rights(URL)      | <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>  |
| Type             | article (author version)   |
| File Information | Ticks Tick Borne Dis_v.7 p.723-729_2016.pdf  |



[Instructions for use](#)

1 **Development of a serodiagnostic multi-species ELISA against**  
2 **Tick-borne encephalitis virus using subviral particles**

3

4 Eri Inagaki, Mizuki Sakai, Minato Hirano, Memi Muto, Shintaro Kobayashi, Hiroaki  
5 Kariwa, Kentaro Yoshii<sup>#</sup>

6

7 Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido  
8 University, Sapporo, Hokkaido 060-0818, Japan

9

10 <sup>#</sup>Corresponding author: Kentaro Yoshii, PhD., DVM.

11 Postal address: Laboratory of Public Health, Graduate School of Veterinary Medicine,  
12 Hokkaido University, kita-18 nishi-9, kita-ku, Sapporo, Hokkaido 060-0818, Japan

13 Tel/fax: +81-11-706-5212

14 E-mail: kyoshii@vetmed.hokudai.ac.jp

15

16 Word count for Abstract: 192

17 Word count for text: 3376

18

19 **Abbreviations**

- 20 AP: alkaline phosphatase
- 21 BHK-21: baby hamster kidney fibroblast
- 22 ELISA: enzyme-linked immunosorbent assay
- 23 FBS: fetal bovine serum
- 24 HEK293T: human embryonic kidney 293T
- 25 HRP: horseradish peroxidase
- 26 JEV: Japanese encephalitis virus
- 27 mAb: monoclonal antibodies
- 28 NT: neutralization test
- 29 OD: optical density
- 30 OPD: *o*-phenylenediamine dihydrochloride
- 31 PAGE: polyacrylamide gel electrophoresis
- 32 PBS: phosphate buffered saline
- 33 PCR: polymerase chain reaction
- 34 PEG: polyethylene glycol
- 35 SDS: sodium dodecyl sulfate
- 36 SPs: subviral particles
- 37 Strep-SP ELISA: ELISA using Strep-SPs
- 38 Strep-SPs: SPs with Strep-tag
- 39 TBEV: Tick-borne encephalitis virus
- 40 WNV: West Nile virus
- 41

42 **Abstract**

43

44 Tick-borne encephalitis virus (TBEV) is a zoonotic agent causing severe  
45 encephalitis in humans. A wide range of animal species could be infected with TBEV in  
46 endemic areas. A serological survey of wild animals is effective in identifying  
47 TBEV-endemic areas. Safe, simple, and reliable TBEV serodiagnostic tools are needed  
48 to test animals. In this study, ELISA was developed to detect anti-TBEV specific  
49 antibodies in multi-species of animals, using recombinant subviral particles (SPs) with  
50 an affinity tag and protein A/G. A Strep-tag was fused at the N terminus of the E protein  
51 of the plasmid coding TBEV prME. The E proteins with Strep-tag were secreted as SPs,  
52 of which Strep-tag was exposed on the surface. The tagged E proteins were associated  
53 with prM. The SPs with Strep-tag were applied as the antigen of ELISA, and  
54 TBEV-specific antibodies were detected by the protein A/G. Compared to neutralization  
55 test results, the ELISA showed 96.8% sensitivity and 97.7% specificity in rodents and  
56 95.1% sensitivity and 96.0% specificity in humans, without cross-reactivity with  
57 antibodies to Japanese encephalitis virus. These results indicate that our ELISA would  
58 be useful to detect TBE-specific antibodies in a wide range of animal species.

59

60 **Keywords;** tick-borne encephalitis virus, flavivirus, subviral particles, ELISA

61

## 62 **Introduction**

63

64 Tick-borne encephalitis virus (TBEV) belongs to the Flaviviridae family and  
65 Flavivirus genus, and causes mild or moderate febrile illness, and subacute or fatal  
66 encephalitis in humans. TBEV is divided into European, Siberian, and Far-Eastern  
67 subtypes. The Far-Eastern subtype is the most lethal. The virus is endemic in many parts  
68 of Europe and Asia (Banzhoff et al., 2008; Gubler, 2007; Ludlam et al., 2006), and more  
69 than 10,000 cases of the disease are reported annually. Therefore, it is an important  
70 disease within the context of public health. TBEV is maintained in transmission cycles  
71 between *Ixodid* ticks and wild mammalian hosts, particularly rodents (Mansfield et al.,  
72 2009). A wide range of animal species are also infected with TBEV by the bite of  
73 infected ticks. To control clinical disease with vaccination of humans, it is important to  
74 specify the TBEV-endemic area and design an effective vaccination plan. An  
75 epizootiological survey of wild animals such as rodents, deer and goats is effective in  
76 detecting TBEV-endemic areas (Gerth et al., 1995; Klaus et al., 2012; Lindhe et al.,  
77 2009; Yoshii et al., 2011). Serological diagnosis is a useful method to perform an  
78 epidemiological survey.

79 A neutralization test (NT) has been used in areas where two or more flaviviruses  
80 are endemic, as it has high specificity for each virus. However, NT is time-consuming,  
81 and high-biosafety-level facilities are required to handle the live virus. An  
82 enzyme-linked immunosorbent assay (ELISA), based on inactivated tick-borne  
83 encephalitis (TBE) virions, is also widely used. ELISA is a useful diagnostic method  
84 because it could be handled safely. However, many commercial TBE-ELISA kits have  
85 shown cross-reactivity against antibodies to other flaviviruses (Dobler et al., 1996;

86 Holzmann et al., 1996; Niedrig et al., 2001a). Commercial ELISA kits are applicable  
87 mainly to infection in humans. A commercial ELISA kit for a wide range of animal  
88 species is currently available, but it is somehow expensive. Therefore, it is important to  
89 develop a safe and simple serological diagnostic method that could be applied to a wide  
90 range of animal species.

91 The expression of the entire prM and E genes are secreted as membrane-bound  
92 subviral particles (SPs) (Allison et al., 1995). The SPs consist of a viral envelope  
93 without a nucleocapsid or genomic RNA. Because SPs maintain antigenicity similar to  
94 that of authentic virions, they have been applied as substitutes for infectious virions in  
95 serological diagnosis (Ferlenghi et al., 2001; Ikawa-Yoshida et al., 2011; Obara et al.,  
96 2006).

97 In this study, we constructed recombinant SPs in which the affinity tag, Strep-tag,  
98 was expressed on the surface. Furthermore, the SPs with Strep-tag (Strep-SPs) were  
99 applied to a new serodiagnostic ELISA that could detect anti-TBEV antibodies in a  
100 wide range of animal species by using protein A/G. The ELISA was evaluated by  
101 comparing the results with those from the NT.

102

## 103 **Materials and Methods**

104

105 **Cell and virus.** Baby hamster kidney fibroblast (BHK-21) cells were cultured on  
106 Eagle's minimum essential medium (Wako, Osaka, Japan) containing 8% fetal bovine  
107 serum (FBS) and were used for NTs. Human embryonic kidney 293T (HEK293T) cells  
108 were cultured at 37 °C in high-glucose Dulbecco's Modified Eagle's medium (Wako)  
109 supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin.

110 The Oshima 5-10 strain of TBEV was used. It was isolated from a dog in

111 Hokkaido in 1995 and classified as the Far Eastern subtype (Takashima et al., 1997).  
112 The virus was propagated by intracerebral inoculation of suckling mice.  
113  
114 **Serum.** Seventy four serum samples from wild rodents (53 *Myodes rufocanus*  
115 *bedfordiae*, 18 *Apodemus speciosus* and one *A. argenteus*) captured in Hokuto,  
116 Hokkaido, between August 1996 and October 1997 were tested for anti-TBEV  
117 antibodies. The animal experiments were performed in accordance with the  
118 recommendations in the Fundamental Guidelines for Proper Conduct of Animal  
119 Experiment and Related Activities in Academic Research Institutions under the  
120 jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology. The  
121 experimental protocols were approved by the Animal Care and Use Committee of the  
122 Hokkaido University (approval number: 13-0119).  
123       One hundred and seven serum samples from TBE-suspected patients were also  
124 tested. The serum samples were obtained from the Far Eastern Medical Center,  
125 Khabarovsk, Russia in 1998. Ten samples from Japanese encephalitis virus (JEV)  
126 -infected Nepalese patients were obtained from Drs. Nakayama and Kurane (National  
127 Institute of Infectious Diseases, Tokyo, Japan). The study was approved by the ethics  
128 committee of Graduate School of Veterinary Medicine, Hokkaido University (Approved  
129 No. 26-1).  
130

131 **Plasmid construction.** The pCAG-TBEV-M-E and pCAG-WNV-M-E plasmids, which  
132 are pCAGGS-based plasmids encoding the TBEV (Oshima 5-10 strain) or West Nile  
133 Virus (WNV; the NY-99 flamingo382-99 strain) signal sequence of prM, prM and E  
134 genes, was constructed as described previously (Yoshii et al., 2003).

135 To construct the pCAG-TBEV-M-StrepE and pCAG-WNV-M-StrepE plasmids,  
136 the coding sequence for the Strep-tag from the pCAG-OSF plasmid (kindly provided by  
137 Dr. Kamitani, Osaka University) was inserted before that for the E proteins. The  
138 pCAG-TBEV-M-E and pCAG-WNV-M-E plasmids were digested by *Age I* and *Pvu II*,  
139 and *Cla I* and *Bgl II*, respectively. The fragments for coding sequences for the  
140 C-terminal prM and signal sequence for E, Strep-tag, Flag-tag, and N-terminal E were  
141 amplified by polymerase chain reaction (PCR) and inserted into the digested plasmids  
142 using the In Fusion cloning kit (TAKARA, Shiga, Japan; Fig. 1).

143

144 **Transfection.** The plasmid was transfected into HEK293T cells using the  
145 X-tremeGENE HP DNA Transfection Reagent (Roche, Basel, Switzerland), following  
146 the manufacturer's instructions. The cells were grown for 24 h at 37°C, and the cells and  
147 culture supernatant were harvested and stored at -80°C.

148 The supernatant containing SPs was concentrated by polyethylene glycol (PEG)  
149 precipitation or ultracentrifugation. In PEG precipitation, the supernatant was mixed  
150 with final concentrations of 10% PEG 8,000 and 1.9% NaCl, and incubated for 2 h at  
151 4°C. The SPs were precipitated by centrifugation at 11,000 x g for 20 min and were  
152 resuspended in phosphate-buffered saline (PBS). In ultracentrifugation, the supernatant  
153 was precipitated by centrifugation at 28,000 rpm for 1 h in CP80MX using P40ST-1239  
154 rotor (Hitachi Koki, Tokyo, Japan), and were resuspended in PBS.



155

156 **Detection of the E proteins by ELISA.** The TBEV-E proteins in the cells and culture  
157 supernatant were treated with or without 1% Triton X-100 and detected by sandwich  
158 ELISA using the monoclonal antibodies (mAb) 1H4 (1:50) and 4H8 (1:1,000),  
159 recognizing the conformational epitopes of the E protein (Komoro et al., 2000). To  
160 detect the E proteins with the Strep-tag, the E proteins were captured by mAb 1H4  
161 (1:50) and the Strep-tag was detected by Strep-Tactin conjugated with  
162 horseradish-peroxidase (HRP; 1:5,000; BIO RAD, Hercules, USA). The color reaction  
163 was developed by adding *o*-phenylenegiamine dihydrochloride (OPD; Wako) in the  
164 presence of 0.07% H<sub>2</sub>O<sub>2</sub> for 30 min at room temperature, and the optical density (OD)  
165 was measured at 450-630 nm.

166

167 **SDS-PAGE and Western Blotting.** The samples were separated on 10%  
168 polyacrylamide-sodium dodecyl sulfate (SDS) gels or commercial 5-12% gradient  
169 polyacrylamide-SDS gels (ATTO, Tokyo, Japan) under non-reducing conditions.  
170 Proteins were transferred to polyvinylidene difluoride membranes, blocked, and  
171 incubated overnight with anti-TBEV E rabbit antibody (1:750 or 1:1,000)(Yoshii et al.,  
172 2004), anti-WNV E mouse antibody (1:1,000; Millipore, Darmstadt, Germany), or  
173 alkaline phosphatase (AP) -conjugated Strep-Tactin (1:1,000 or 1:5,000; BIO RAD).  
174 The rabbit antibodies were detected by AP or HRP-conjugated anti-rabbit IgG  
175 secondary antibodies (1:5,000; Jackson ImmunoResearch, Pennsylvania, USA), and the  
176 mouse antibodies were detected by HRP-conjugated anti-mouse IgG secondary  
177 antibodies (1:10,000).

178 For the affinity precipitation, the E proteins in the cell lysate or supernatant were

179 precipitated using a Strep-Tactin Sepharose beads kit (IBA, Gottingen, Germany) for 4  
180 h at 4°C. They were used for subsequent SDS-polyacrylamide gel electrophoresis  
181 (PAGE) and western blotting analysis. The proteins on the membranes were incubated  
182 with the anti-prM (1:300) and anti-E antibodies (1:750), followed by the AP-conjugated  
183 secondary antibody (1:10,000).

184 Bands were visualized using the AP detection kit (Merck, Darmstadt, Germany) or  
185 chemiluminescent HRP substrate (Millipore).

186

187 ***Sucrose density-gradient centrifugation.*** The SPs were centrifuged by overnight  
188 equilibrium density centrifugation in a 10-50% sucrose gradient at 28,000 rpm at 4°C  
189 for 16 h. Fractions of 0.5 ml were collected from the top of the tubes and analyzed by  
190 ELISA.

191

192 ***Serodiagnostic ELISA.*** Ninety-six well EIA plates (Corning, New York, USA) were  
193 coated with Strep-Tactin (1:1,000) overnight at 4°C and then blocked with Block Ace  
194 (DS Pharma Biomedical, Osaka, Japan). After washing with PBS containing 0.05%  
195 Tween 20, the antigen Strep-SPs were added (1:5 diluted of PEG precipitated  
196 supernatant), followed by serum samples (1:200). The TBEV-specific antibodies were  
197 detected by Protein A/G conjugated with HRP (1:2,000; Thermo Fisher Scientific,  
198 Massachusetts, USA), and reacted with OPD. Negative control antigens were prepared  
199 from the supernatant of untransfected HEK293T cells. The results were recorded as the  
200 P/N ratio (OD value using Strep-SPs to that using negative control antigen). The results  
201 of ELISA were compared with those of NT and were assessed by Pearson's chi-squared  
202 test in a 2 × 2 contingency table.

203 The commercial Immunozytm FSME IgG kit (Progen Biotechnik, Heidelberg,

204 Germany) were used for comparison with the strep-SP ELISA.

205

206 **Neutralization test.** TBEV was incubated with serially diluted serum and inoculated to  
207 BHK cells. The cells were incubated with minimum essential medium containing 1.5 %  
208 carboxymethyl cellulose and 2 % FBS for 4 days. After 4 days of incubation, the cells  
209 were fixed with 10 % formalin and stained with 0.1 % crystal violet. Serum samples  
210 that produced a 50 % reduction in plaque formation of the TBEV on BHK cells in  
211 12-well plates were determined by immunocytochemical staining. Serum samples  $\geq 1:20$   
212 were judged to be positive for neutralizing antibodies against TBEV.

213

## 214 **Results**

215

216 **Expression and characterization of Strep-SPs.** The expression of the entire prM and E  
217 proteins, leading to the secretion of SPs, has been reported (Allison et al., 1995). To  
218 obtain the SPs on which the Strep-tag was superficially expressed, we constructed a  
219 plasmid expressing the prM and E proteins with the tag fused to the N-terminus of the E  
220 protein (the pCAG-TBEV-M-StrepE and pCAG-WNV-E-StrepE plasmids; Fig. 1). The  
221 Strep-tag is an eight-residue minimal peptide sequence (WSHPQFEK), with an intrinsic  
222 affinity toward streptavidin. Strep-Tactin was developed to improve the peptide-binding  
223 capacity of streptavidin. (Schmidt, 2007).

224 HEK293T cells were transfected with pCAG-TBEV-M-StrepE or  
225 pCAG-TBE-M-E, and the expression and secretion of the E proteins with the Strep-tag  
226 were detected by Western blotting. In both the cell lysate and supernatant, the E proteins  
227 were detected by anti-E specific antibodies, and the E proteins with the Strep-tag were  
228 detected by Strep-Tactin from the cells transfected with pCAG-TBEV-M-StrepE (Fig.

229 2A). The band for the E proteins with the Strep-tag from pCAG-TBEV-M-StrepE  
230 migrated slower than that of the E proteins without the tag from pCAG-TBE-M-E. The  
231 transfection of pCAG-WNV-M-StrepE resulted in the expression and secretion of the E  
232 protein of WNV with Strep-tag, as observed in the transfection with  
233 pCAG-TBEV-M-StrepE (Fig. 2B).

234 To examine whether the Strep-tag was expressed on the surface of the secreted SPs,  
235 the E proteins in the secreted SPs were directly captured by anti-E specific antibody and  
236 Strep-tag expressed on the surface of SPs was detected by Strep-Tactin by ELISA (Fig.  
237 2C). While no reactivity was observed in the SPs from pCAG-TBE-M-E, the Strep-tag  
238 of the E proteins in the SPs from pCAG-TBEV-M-StrepE reacted with Strep-Tactin.  
239 These data indicated that the Strep-tag of the E protein in the supernatant was exposed  
240 on the surface of the SPs.

241 In intracellular immature virions, the prM and E proteins are associated to form  
242 prM-E heterodimers, which is an essential step in the proper maturation of the E protein  
243 (Allison et al., 1999). To confirm whether the addition of the Strep-tag affect the  
244 interaction between prM and E, the E protein with the Strep-tag in the cell lysate was  
245 precipitated by Strep-Tactin beads and separated by SDS-PAGE. The E and prM  
246 proteins were detected by Western blotting (Fig. 2d). The bands for E and prM were  
247 detected in the precipitated cell lysate. This result indicated that the interaction between  
248 the E and prM proteins was not affected by addition of the Strep-tag.

249 To examine the physical properties of the expressed E protein with the Strep-tag in  
250 the medium, the supernatants were subjected to sucrose density-gradient centrifugation  
251 analysis. The E protein in each gradient fraction was detected by ELISA. The signals of  
252 the E protein in the Strep-SPs were seen at a sucrose density of 1.13-1.16 g/cm<sup>3</sup>, which

253 was almost identical to that of SPs (1.12-1.14 g/cm<sup>3</sup>), and it was disturbed by the  
254 treatment of Triton-X 100 (Fig. 3). This result indicated that the E protein with the  
255 Strep-tag was secreted as a membrane-bound structure similar to SPs.

256

257 ***Serodiagnostic Strep-SP ELISA.*** To examine whether ELISA using Strep-SPs  
258 (Strep-SP ELISA) as the antigen could be used to detect the TBEV specific antibodies in  
259 serum samples from TBEV-infected individuals, several serially diluted wild rodent and  
260 human sera were examined (Fig. 4). In this ELISA, Strep-SPs were captured by plate  
261 coated with Strep-Tactin. The TBEV-specific antibodies in the serum reacted with the  
262 Strep-SPs and detected by Protein A/G. In both rodent and human sera, all NT positive  
263 sera had high P/N ratios, while NT negative sera had a P/N ratio of about 1.0 in  
264 Strep-SP ELISA.

265 To determine whether Strep-SP ELISA was appropriate for serodiagnosis, rodent  
266 and human serum samples were tested for TBEV antibodies, and the results were  
267 compared with NT results. Thirty-one TBEV positive and 43 negative rodent serum  
268 samples captured in TBEV-endemic areas were tested using Strep-SP ELISA, and the  
269 specificity and sensitivity were determined by comparison with the NT results using the  
270 corresponding cut-off value (Fig. 5A; Table 1). The difference between the sensitivity  
271 and specificity was minimal when a cut off value of 1.34 was used. In this case, for  
272 serodiagnosis of TBEV in rodents, Strep-SP ELISA had 96.8% sensitivity and 97.7%  
273 specificity compared with the NT result ( $P < 0.001$ ). We also tested 107 TBE suspected  
274 human serum samples (Fig. 5B; Table 2). There were 82 TBEV-positive sera and 25  
275 negative sera. The sensitivity of Strep-SPs ELISA was 95.1% and the specificity was  
276 96.0% when the cut off value was 1.202 ( $P < 0.001$ ). To determine if Strep-SP ELISA

277 could distinguish between anti-JEV and anti-TBEV antibodies, 10 serum samples  
278 confirmed to have anti-JEV antibodies were tested. While commercial ELISA gave  
279 inconclusive results in 3 samples, all samples were assessed to be negative in Strep-SP  
280 ELISA, indicating that Strep-SP ELISA is not cross-reactive with the JEV antibody  
281 (Table 3).  
282

283 **Discussion**

284

285 To identify TBEV endemic areas, it is important to conduct a serological survey of  
286 wild animals (Yoshii et al., 2011). NT is the serodiagnostic method used to detect  
287 TBEV-specific antibodies regardless of animal species, but it requires time and a  
288 high-level of biocontainment for its application. Therefore, the application of SPs could  
289 be a useful approach to developing a serological diagnosis in a wide range of species  
290 without high-biosafety facilities. In this study, we prepared recombinant SPs of TBEV  
291 with the Strep-tag and applied them to serodiagnostic ELISA for TBEV-infected human  
292 and wild rodent sera.

293 The flavivirus E proteins have been shown to be important for immunodiagnostic  
294 and immunotherapeutic applications in several studies (Hermida et al., 2006; Holbrook  
295 et al., 2004; Wu et al., 2004). However, purification of the secreted proteins is  
296 cumbersome. Some fusion partners were used to easily purify tagged E-proteins  
297 (Beasley et al., 2004; Holbrook et al., 2004). The Strep-tag could be easily fused to a  
298 recombinant polypeptide in various fashions (Schmidt, 2007), and in this study, this tag  
299 was fused to the E protein for efficient capture of the Strep-SP antigen in ELISA  
300 without affecting antigenicity. In a recent study, it was reported that the antigenic  
301 structures of the E proteins were disturbed when the ELISA plate was coated directly  
302 with the viral particles as a solid-phase antigen (Stiasny et al., 2006). To avoid this  
303 antigenic disturbance by direct coating, the Strep-SPs were captured by Strep-Tactin  
304 coated on the plate in our ELISA.

305 In native virions, the E proteins are homodimers, extending in parallel on the  
306 surface of the viral envelope membrane (Rey et al., 1995). The E protein is composed of

307 ectodomains (I, II, and III), stem, and a trans-membrane anchor region. Domain III is  
308 known to possess the major antigenic epitopes (Chávez et al., 2010). In this study, the  
309 Strep-tag was fused at the N terminus of E, without disturbing the antigenic and  
310 conformational structures. Our results indicated that the Strep-tagged E proteins were  
311 secreted as SPs and the Strep-tag was exposed on the surface of the particles (Fig. 2).

312 The prM and E proteins must associate with each other shortly after synthesis for  
313 proper folding of E proteins (Lorenz et al., 2002). The conversion of immature virus  
314 particles to mature virions occurs in the secretory pathway and coincides with cleavage  
315 of prM into pr and M by the Golgi-resident furin or a furin-like enzyme (Stadler et al.,  
316 1997). The pr-region of prM is thought to stabilize the E protein and keep it from  
317 undergoing rearrangement to the fusogenic form in the reduced pH environment of the  
318 early secretory pathway (Guirakhoo et al., 1991). In a previous study, intracellular E  
319 proteins that were not fully mature were applied as antigens of serodiagnostic ELISA  
320 (Yoshii et al., 2003), but they showed relatively lower sensitivity and specificity,  
321 indicating that proper maturation is important to retain native antigenicity. In our study,  
322 addition of the Strep-tag in the E protein did not disturb the interaction between prM  
323 and E (Fig. 2D), and membrane-bound structures similar to authentic SPs were secreted  
324 in the culture fluid (Fig.3). These results suggested that the E protein with the Strep-tag  
325 was secreted through the proper maturation and secretory pathways by the support of  
326 prM.

327 In Strep-SP ELISA, Strep-SPs were used to detect TBEV-specific antibodies, and  
328 protein A/G was applied to detect the antibodies in a wide range of animal species.  
329 Strep-SP ELISA of both rodent and human sera showed over 95% sensitivity and  
330 specificity, indicating that it had enough diagnostic accuracy for screening purposes. It



331 was reported that infection and/or vaccination with other flaviviruses, including yellow  
332 fever virus, dengue virus, WNV, and JEV, could induce cross-reactive antibodies  
333 (Dobler et al., 1996; Holzmann et al., 1996; Niedrig et al., 2001a). Our Strep-SP ELISA  
334 showed no cross-reactivity with JEV antibodies while the commercial TBEV ELISA  
335 showed cross-reactivity in previous studies (Niedrig et al., 2001b; Obara et al., 2006). A  
336 recent report showed that the broadly flavivirus cross-reactive antibodies recognized  
337 antigenic sites that were not fully accessible on the surfaces of native TBE virions, but  
338 became significantly more exposed after disintegration of the envelope (Stiasny et al.,  
339 2006). It also suggested that the inactivation of virions in commercial ELISA might  
340 cause denaturation and/or disintegration on the virions, resulting in cross-reactivity  
341 against numerous flaviviruses (Heinz et al., 1995). However, in our Strep-SP ELISA,  
342 Strep-SPs did not require formalin inactivation, and it might lead to conservation of the  
343 native structure of particles in which the cross-reactive epitope were not fully  
344 accessible.

345 In our ELISA, Protein A/G was used to detect specific antibodies in rodent and  
346 human sera. Protein A/G is a product that has the Fc-binding domains of both Protein A  
347 and Protein G, and could be used to detect immunoglobulin in serological diagnosis  
348 (Bhide, 2004), due to its binding spectra toward polyclonal immunoglobulin from a  
349 wide range of animal species (Eliasson et al., 1988). In this study, our Strep-SP ELISA  
350 was examined in human and wild rodent antibodies. This ELISA could be further  
351 applied to numerous animal species that could be mammalian hosts of TBEV. Binding  
352 capacity of Protein A/G to mammalian immunoglobulin differs among species (Stobel  
353 et al., 2002), and our ELISA should be examined in more diverse species for efficacy of  
354 detection.

355 In summary, Strep-SP ELISA demonstrated high sensitivity and specificity, with no  
356 cross-reactivity with anti-JEV antibodies. Further examination by using sera from  
357 imported dengue case or yellow fever vaccination would expand the availability of the  
358 ELISA for diagnosis in human. The features of SP secretion are common in flaviviruses  
359 (Allison et al., 1995; Fonseca et al., 1994; Mason et al., 1991; Pincus et al., 1992). The  
360 strategy developed in this study could be applied to serodiagnostic methods for other  
361 flaviviruses, as shown in the results of the secretion of Strep-SPs of WNV. Strep-SP  
362 ELISA would be useful for epidemiological and epizootiological surveys in areas where  
363 several flaviviruses are endemic.

364

#### 365 **Acknowledgments**

366 We thank Dr. Nakayama and Dr. Kurane for providing serum samples from JE-infected  
367 patients, and Ms. Ishizuka for technical assistance.

368 This work was supported by Grants-in-Aid for Scientific Research (24780293,  
369 25304040 and 26660220) from the Ministry of Education, Culture, Sports, Sciences and  
370 Technology of Japan, Health Sciences Grants for Research on Emerging and  
371 Re-emerging Infectious Disease from Ministry of Health, Labour and Welfare of Japan.

372 No competing financial interests exist in this paper.

373

374

#### 375 **Reference**

376

377 Allison, S.L., Stadler, K., Mandl, C.W., Kunz, C., Heinz, F.X., 1995. Synthesis and Secretion  
378 of Recombinant Tick-Borne Encephalitis-Virus Protein-E in Soluble and Particulate Form. *J.*  
379 *Virol.* 69, 5816-5820.

380 Allison, S.L., Stiasny, K., Stadler, K., Mandl, C.W., Heinz, F.X., 1999. Mapping of functional  
381 elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. *J.*  
382 *Virology* 73, 5605-5612.

383 Banzhoff, A., Bröker, M., Zent, O., 2008. Protection against tick-borne encephalitis (TBE) for  
384 people living in and travelling to TBE-endemic areas. *Travel Medicine and Infectious*  
385 *Disease* 6, 331-341.

386 Beasley, D.W., Holbrook, M.R., Travassos Da Rosa, A.P., Coffey, L., Carrara, A.S.,  
387 Phillippi-Falkenstein, K., Bohm, R.P., Jr., Ratterree, M.S., Lillibridge, K.M., Ludwig, G.V.,  
388 Estrada-Franco, J., Weaver, S.C., Tesh, R.B., Shope, R.E., Barrett, A.D., 2004. Use of a  
389 recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile  
390 virus infection. *Journal of clinical microbiology* 42, 2759-2765.

391 Bhide, M.R.M., 2004. Protein A/G dependent ELISA a promising diagnostic tool in Lyme  
392 disease seroprevalence in game animals and hunting dogs. *Comparative immunology,*  
393 *microbiology and infectious diseases* 27, 191-199.

394 Chávez, J.H., Silva, J.R., Amarilla, A.A., Moraes Figueiredo, L.T., 2010. Domain III peptides  
395 from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for  
396 immunization. *Biologicals* 38, 613-618.

397 Dobler, G., Treib, J., Kiessig, S.T., Blohn, W.V., Frosner, G., Haass, A., 1996. Diagnosis of  
398 tick-borne encephalitis: evaluation of sera with borderline titers with the TBE-ELISA.  
399 *Infection* 24, 405-406.

400 Eliasson, M., Olsson, A., Palmcrantz, E., Wiberg, K., Inganas, M., Guss, B., Lindberg, M.,  
401 Uhlen, M., 1988. Chimeric IgG-binding receptors engineered from staphylococcal protein A  
402 and streptococcal protein G. *The Journal of biological chemistry* 263, 4323-4327.

403 Ferlenghi, I., Clarke, M., Ruttan, T., Allison, S.L., Schalich, J., Heinz, F.X., Harrison, S.C.,  
404 Rey, F.A., Fuller, S.D., 2001. Molecular Organization of a Recombinant Subviral Particle  
405 from Tick-Borne Encephalitis Virus. *Molecular Cell* 7, 593-602.

406 Fonseca, B.A., Pincus, S., Shope, R.E., Paoletti, E., Mason, P.W., 1994. Recombinant vaccinia  
407 viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in  
408 mice. *Vaccine* 12, 279-285.

409 Gerth, H.J., Grimshandl, D., Stage, B., Doller, G., Kunz, C., 1995. Roe deer as sentinels for  
410 endemicity of tick-borne encephalitis virus. *Epidemiology and infection* 115, 355-365.

411 Gubler, D.J., 2007. The continuing spread of West Nile virus in the western hemisphere.  
412 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*  
413 *America* 45, 1039-1046.

414 Guirakhoo, F., Heinz, F.X., Mandl, C.W., Holzmann, H., Kunz, C., 1991. Fusion activity of  
415 flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis

416 virions. *The Journal of general virology* 72 ( Pt 6), 1323-1329.

417 Heinz, F.X., Allison, S.L., Stiasny, K., Schalich, J., Holzmann, H., Mandl, C.W., Kunz, C.,  
418 1995. Recombinant and virion-derived soluble and particulate immunogens for vaccination  
419 against tick-borne encephalitis. *Vaccine* 13, 1636-1642.

420 Hermida, L., Bernardo, L., Martín, J., Alvarez, M., Prado, I., López, C., Sierra, B.d.l.C.,  
421 Martínez, R., Rodríguez, R., Zulueta, A., Pérez, A.B., Lazo, L., Rosario, D., Guillén, G.,  
422 Guzmán, M.G., 2006. A recombinant fusion protein containing the domain III of the  
423 dengue-2 envelope protein is immunogenic and protective in nonhuman primates. *Vaccine*  
424 24, 3165-3171.

425 Holbrook, M.R., Shope, R.E., Barrett, A.D., 2004. Use of recombinant E protein domain  
426 III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis  
427 serocomplex flaviviruses from mosquito-borne flaviviruses. *Journal of clinical microbiology*  
428 42, 4101-4110.

429 Holzmann, H., Kundi, M., Stiasny, K., Clement, J., McKenna, P., Kunz, C., Heinz, F.X., 1996.  
430 Correlation between ELISA, hemagglutination inhibition, and neutralization tests after  
431 vaccination against tick-borne encephalitis. *Journal of medical virology* 48, 102-107.

432 Ikawa-Yoshida, A., Yoshii, K., Kuwahara, K., Obara, M., Kariwa, H., Takashima, I., 2011.  
433 Development of an ELISA system for tick-borne encephalitis virus infection in rodents.  
434 *Microbiology and immunology* 55, 100-107.

435 Klaus, C., Beer, M., Saier, R., Schau, U., Moog, U., Hoffmann, B., Diller, R., Suss, J., 2012.  
436 Goats and sheep as sentinels for tick-borne encephalitis (TBE) virus--epidemiological  
437 studies in areas endemic and non-endemic for TBE virus in Germany. *Ticks and tick-borne*  
438 *diseases* 3, 27-37.

439 Komoro, K., Hayasaka, D., Mizutani, T., Kariwa, H., Takashima, I., 2000. Characterization  
440 of monoclonal antibodies against Hokkaido strain tick-borne encephalitis virus.  
441 *Microbiology and immunology* 44, 533-536.

442 Lindhe, K.E., Meldgaard, D.S., Jensen, P.M., Houser, G.A., Berendt, M., 2009. Prevalence of  
443 tick-borne encephalitis virus antibodies in dogs from Denmark. *Acta veterinaria*  
444 *Scandinavica* 51, 56.

445 Lorenz, I.C., Allison, S.L., Heinz, F.X., Helenius, A., 2002. Folding and dimerization of  
446 tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. *J.*  
447 *Virol.* 76, 5480-5491.

448 Ludlam, C.A., Powderly, W.G., Bozzette, S., Diamond, M., Koerper, M.A., Kulkarni, R.,  
449 Ritchie, B., Siegel, J., Simmonds, P., Stanley, S., Tapper, M.L., von Depka, M., 2006. Clinical  
450 perspectives of emerging pathogens in bleeding disorders. *The Lancet* 367, 252-261.

451 Mansfield, K.L., Johnson, N., Phipps, L.P., Stephenson, J.R., Fooks, A.R., Solomon, T., 2009.

452 Tick-borne encephalitis virus - a review of an emerging zoonosis. *Journal of General Virology*  
453 90, 1781-1794.

454 Mason, P.W., Pincus, S., Fournier, M.J., Mason, T.L., Shope, R.E., Paoletti, E., 1991.  
455 Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the  
456 structural membrane proteins and induce high levels of protection against lethal JEV  
457 infection. *Virology* 180, 294-305.

458 Niedrig, M., Vaisviliene, D., Teichmann, A., Klockmann, U., Biel, S.S., 2001a. Comparison of  
459 six different commercial IgG-ELISA kits for the detection of TBEV-antibodies. *Journal of*  
460 *clinical virology : the official publication of the Pan American Society for Clinical Virology* 20,  
461 179-182.

462 Niedrig, M., Vaisviliene, D., Teichmann, A., Klockmann, U., Biel, S.S., 2001b. Comparison of  
463 six different commercial IgG-ELISA kits for the detection of TBEV-antibodies. *Journal of*  
464 *Clinical Virology* 20, 179-182.

465 Obara, M., Yoshii, K., Kawata, T., Hayasaka, D., Goto, A., Mizutani, T., Kariwa, H.,  
466 Takashima, I., 2006. Development of an enzyme-linked immunosorbent assay for serological  
467 diagnosis of tick-borne encephalitis using subviral particles. *Journal of virological methods*  
468 134, 55-60.

469 Pincus, S., Mason, P.W., Konishi, E., Fonseca, B.A., Shope, R.E., Rice, C.M., Paoletti, E.,  
470 1992. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus  
471 protects mice from lethal yellow fever encephalitis. *Virology* 187, 290-297.

472 Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C., 1995. The envelope glycoprotein  
473 from tick-borne encephalitis virus at 2 Å resolution. *Nature* 375, 291-298.

474 Schmidt, T.G.M.T.G., 2007. The Strep-tag system for one-step purification and high-affinity  
475 detection or capturing of proteins. *Nature protocols* 2, 1528-1535.

476 Stadler, K., Allison, S.L., Schalich, J., Heinz, F.X., 1997. Proteolytic activation of tick-borne  
477 encephalitis virus by furin. *J Virol* 71, 8475-8481.

478 Stiasny, K., Kiermayr, S., Holzmann, H., Heinz, F.X., 2006. Cryptic properties of a cluster of  
479 dominant flavivirus cross-reactive antigenic sites. *J Virol* 80, 9557-9568.

480 Stobel, K., Schonberg, A., Staak, C., 2002. A new non-species dependent ELISA for detection  
481 of antibodies to *Borrelia burgdorferi* s. l. in zoo animals. *International journal of medical*  
482 *microbiology : IJMM* 291 Suppl 33, 88-99.

483 Takashima, I., Morita, K., Chiba, M., Hayasaka, D., Sato, T., Takezawa, C., Igarashi, A.,  
484 Kariwa, H., Yoshimatsu, K., Arikawa, J., Hashimoto, N., 1997. A case of tick-borne  
485 encephalitis in Japan and isolation of the the virus. *Journal of clinical microbiology* 35,  
486 1943-1947.

487 Wu, Y., Zhang, F., Ma, W., Song, J., Huang, Q., Zhang, H., 2004. A Plasmid Encoding

488 Japanese Encephalitis Virus PrM and E Proteins Elicits Protective Immunity in Suckling  
489 Mice. *Microbiology and immunology* 48, 585-590.

490 Yoshii, K., Hayasaka, D., Goto, A., Obara, M., Araki, K., Yoshimatsu, K., Arikawa, J., Ivanov,  
491 L., Mizutani, T., Kariwa, H., Takashima, I., 2003. Enzyme-linked immunosorbent assay  
492 using recombinant antigens expressed in mammalian cells for serodiagnosis of tick-borne  
493 encephalitis. *Journal of virological methods* 108, 171-179.

494 Yoshii, K., Konno, A., Goto, A., Nio, J., Obara, M., Ueki, T., Hayasaka, D., Mizutani, T.,  
495 Kariwa, H., Takashima, I., 2004. Single point mutation in tick-borne encephalitis virus prM  
496 protein induces a reduction of virus particle secretion. *The Journal of general virology* 85,  
497 3049-3058.

498 Yoshii, K., Mottate, K., Omori-Urabe, Y., Chiba, Y., Seto, T., Sanada, T., Maeda, J., Obara, M.,  
499 Ando, S., Ito, N., Sugiyama, M., Sato, H., Fukushima, H., Kariwa, H., Takashima, I., 2011.  
500 Epizootiological study of tick-borne encephalitis virus infection in Japan. *The Journal of*  
501 *veterinary medical science / the Japanese Society of Veterinary Science* 73, 409-412.

502

503

504

505 **Figure legend**

506

507 **Fig. 1. Schematic of the plasmid expressing SPs with Strep-tag.**

508 The sequence for the Strep-tag was fused to the N' terminus of the E protein.

509

510 **Fig. 2. Expression and secretion of the E protein with Strep-tag.**

511 (A) HEK293T cells were transfected with pCAG-TBE-M-StrepE, pCAG-TBE-M-E, or  
512 no plasmid (mock). Twenty-four hours after transfection, the E protein in the cell lysate  
513 and supernatant was detected by Western blotting analysis using anti-E antibody or  
514 Strep-Tactin.

515 (B) HEK293T cells were transfected with pCAG-WNV-M-StrepE, or no plasmid  
516 (mock). Twenty-four hours after transfection, the E protein in the cell lysate and  
517 PEG-precipitated supernatant was detected by Western blotting analysis using  
518 anti-WNV-E-antibody or Strep-Tactin.

519 (C) The E protein secreted into the culture medium was captured by anti-E mAb without  
520 detergent and the reactivity against Strep-Tactin was examined.

521 (D) Interaction between the prM and StrepE proteins. The E protein with Strep-tag in  
522 the cell lysate was precipitated using Strep-Tactin and separated by SDS-PAGE. Bands  
523 corresponding to each protein were detected using anti-prM and anti-E antibodies.

524

525 **Fig. 3. Equilibrium banding profiles of SPs.**

526 Supernatant of cells transfected with pCAG-TBE-ME (gray circle) or  
527 pCAG-TBEV-M-StrepE with or without treatment with TritonX-100 (black or white  
528 circles, respectively) was subjected to equilibrium density centrifugation and was

529 examined for distribution of the E protein by ELISA. The level of the E protein in the  
530 peak fraction was set at 1.0.

531

532 **Fig. 4. Titration curve of TBEV antibody positive (A) wild rodents or (B) human**  
533 **sera for Strep-SP ELISA.**

534 Two TBEV negative sera were used as controls. All sera were serially diluted and tested  
535 in duplicate.

536

537 **Fig. 5. Relationship between cut-off value, sensitivity, and specificity for the**  
538 **Strep-SP ELISA.**


539 Seventy-four wild rodents sample (A) and 112 human (B) samples were tested for  
540 TBEV antibodies.

541

542




**Fig. 1.** Inagaki *et al.*,




**Fig. 2. Inagaki *et al.*,**

**(A)**




**(B)**




**Fig. 2. Inagaki *et al.*,**


(C)



(D)




**Fig. 3.** Inagaki *et al.*,




**Fig. 4.** Inagaki *et al.*,

**(A)** wild rodent sera




**(B)** human sera




**Fig. 5. Inagaki *et al.*,**

(A) wild rodent sera



(B) human sera



**Table 1. Comparison of the results obtained by neutralization and Strep-SP ELISA in rodent serum.**

| Neutralization test | Strep-SP ELISA |          | Total |
|---------------------|----------------|----------|-------|
|                     | Positive       | Negative |       |
| Positive            | 30             | 1        | 31    |
| Negative            | 1              | 42       | 43    |

**Table 2. Comparison of the results obtains by neutralization and Strep-SP ELISA in human serum.**

| Neutralization test | Strep-SP ELISA |          | Total |
|---------------------|----------------|----------|-------|
|                     | Positive       | Negative |       |
| Positive            | 78             | 4        | 82    |
| Negative            | 1              | 24       | 25    |



**Table 3. Cross-reactivity of JE patient sera to TBEV by commercial ELISA and strep-SP ELISA**

| Patient no. | Commercial<br>ELISA | strep-SP<br>ELISA |
|-------------|---------------------|-------------------|
| 1           | ± <sup>a</sup>      | —                 |
| 2           | —                   | —                 |
| 3           | —                   | —                 |
| 4           | —                   | —                 |
| 5           | —                   | —                 |
| 6           | —                   | —                 |
| 7           | —                   | —                 |
| 8           | —                   | —                 |
| 9           | ±                   | —                 |
| 10          | ±                   | —                 |

<sup>a</sup> boudary